Molecular Diagnosis of Systemic Autoinflammatory Diseases

Genetic Disease Clinical Trial

— SAIDiag  

Official title:

Molecular Diagnosis of Systemic Autoinflammatory Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05364294
• Other study ID #: C20-97
• Status: Recruiting
• Start date: May 18, 2022
• Est. completion date: May 2, 2033

Study information

• Verified date: January 2024
• Source: Institut National de la Santé Et de la Recherche Médicale, France
• Contact: Irina GIURGEA
• Phone: +33144735295
• Email: irina.giurgea[@]inserm.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Systemic autoinflammatory diseases (SAIDs) are a set of rare clinically and genetically heterogeneous conditions. The project proposes to identify novel genes and specific signatures in subgroups of patients with SAIDs.

Description:

SAIDs are characterized by long dormant periods with no or only minor clinical symptoms interrupted by febrile crises accompanied by serous and synovial membrane inflammation that spontaneously resolves. Over the last decades, more than 50 genes encoding key components of the innate immune system have been identified to be involved in the pathophysiology of SAIDs, with both germline and somatic mosaic variations. When disease-causing variations are identified, specific biotherapies are proposed depending on the involved gene and pathway. However, despite these scientific advances, most SAIDs (70%) are of unknown etiology, the diagnosis is made with significant delay, and no targeted therapy can be suggested. This project aims to generate specific understanding and develop strategies for SAID patients with unknown etiology. The investigators aim to advance our understanding of SAIDs pathophysiology, find the disease-causing gene variations and identify the involved cellular pathways that should accelerate correct diagnosis and personalize treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: May 2, 2033
• Est. primary completion date: May 31, 2032
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 1 Week to 120 Years

Eligibility

Inclusion Criteria:

• A patient presenting with a clinical and biological aseptic inflammatory syndrome associating one or more of the following signs: spontaneously resolving fever, abdominal (pain, diarrhea), locomotor (arthralgia, myalgia), thoracic (pain, pericarditis), cutaneous, sensory (uveitis, deafness), or renal (amyloidosis) involvement.

Exclusion Criteria:

• Adult subject to legal protection measures (guardianship, curatorship, safeguard of justice).

Related Conditions & MeSH terms

• Genetic Disease
• Genetic Diseases, Inborn
• Inflammatory Disease
• Molecular Sequence Variation
• Somatic Mutation

Locations

Country	Name	City	State
France	Trousseau Hospital	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To identify SAIDs disease-causing mutations and genes and to explore specific biological signatures.	Molecular studies will be performed through the use of a SAID next generation sequencing (NGS) gene panel, followed by whole exome/genome sequencing (WES/WGS) in patients with no obvious genetic abnormality identified by the gene panel. When possible trio studies (the patient and his parents) will be performed in order to facilitate the interpretation of the molecular variants. Transcriptomics and cytokines profiles will be performed on whole blood cells to identify weakly expressed genes/proteins and by single cell experiments in order to assess cell-specific expression. These data will permit to better shape functional studies and to explore specific biological signatures.	Anytime in the period of 10 years
Primary	To identify novel and better assess the disease pathways	Functional studies will be performed to evaluate the pathogenicity of the identified molecular variants, to assess the involvement of new candidate genes in SAIDs, to characterize the molecular networks to which the corresponding proteins belong and to open up new therapeutic avenues.	Anytime in the period of 10 years
Secondary	To propose personalized treatment options	Depending on the disease gene identified and on the involved signalling pathway, specific biotherapies could be proposed to SAID patients.	Anytime in the period of 10 years